Comparison of varicella zoster antibody titers in patients given intravenous immune serum globulin or varicella zoster immune globulin.
We compared the VZV IgG antibody titers after administration of varicella zoster immune globulin and serum immune globulin intravenously (IGIV) in VZV seronegative pediatric patients with cancer. Four patients received VZIG at standard doses; four received IGIV at 4 ml/kg every 4 weeks for four doses; and five received IGIV at 6 ml/kg every 6 weeks for two to four doses. VZV antibody titers were measured by radiommunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), indirect fluorescent antibody assay (IFA), and neutralizing antibody assay. The mean peak and trough VZV titers by RIA were comparable in all three groups: 1:724 at 4 weeks after VZIG, 1:2048 at 4 weeks after 4 ml/kg IGIV, and 1:776 at 6 weeks after 6 ml/kg IGIV. The titers measured by ELISA, IFA, and neutralizing antibody were comparable after VZIG or IGIV. The VZV titers by RIA were maintained at greater than or equal to 1:1024 after subsequent doses of 4 ml/kg IGIV, and at greater than or equal to 1:256 after subsequent doses of 6 ml/kg IGIV. Adverse effects were rare. The VZV antibody titers assessed 4 to 6 weeks after IGIV administration were equivalent to the titers measured 4 weeks after administration of VZIG.
D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis*; D002644:Chickenpox / Q000276:immunology / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005455:Fluorescent Antibody Technique; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007106:Immune Sera / Q000008:administration & dosage*; D007263:Infusions, Parenteral; D009369:Neoplasms / Q000150:complications; D011863:Radioimmunoassay
D000914:Antibodies, Viral; D007106:Immune Sera; C030799:varicella-zoster immune globulin